ImmunityBio Simulations Reveal Why the New Strain of SARS-CoV-2 in South Africa is Spreading Fast and May ‘Escape’ Existing Immunity

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, just reported their findings from a follow-up Molecular Dynamics (MD) simulation study of the SARS-CoV-2 spike receptor binding domain (RBD) and its binding to its receptor on human cells, angiotensin-converting enzyme 2 (ACE2). In the first study, “Millisecond-scale molecular dynamics simulation of spike RBD structure reveals evolutionary adaption of SARS-CoV-2 to stably bind ACE2” using exceptiona

Click to view original post